Mason Carrico
Stock Analyst at Stephens & Co.
(3.48)
# 907
Out of 5,182 analysts
71
Total ratings
44.12%
Success rate
7.67%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $200.17 | +17.40% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.58 | +26.58% | 6 | Nov 10, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $9.02 | +21.95% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $35.65 | +87.94% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $126.92 | -17.27% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $21.37 | -34.49% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $21.91 | +82.57% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $119.63 | -3.87% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $33.43 | +34.61% | 7 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $83.09 | -33.81% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.57 | +31.29% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $26.71 | -36.34% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $64.40 | -19.25% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $4.84 | +313.22% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $24.69 | +66.06% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $200.17
Upside: +17.40%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.58
Upside: +26.58%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $9.02
Upside: +21.95%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $35.65
Upside: +87.94%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $126.92
Upside: -17.27%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $21.37
Upside: -34.49%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $21.91
Upside: +82.57%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $119.63
Upside: -3.87%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $33.43
Upside: +34.61%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $83.09
Upside: -33.81%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.57
Upside: +31.29%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $26.71
Upside: -36.34%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $64.40
Upside: -19.25%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $4.84
Upside: +313.22%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $24.69
Upside: +66.06%